Skip to main content
Top
Published in: Current Treatment Options in Gastroenterology 1/2023

Open Access 02-03-2023 | Endoscopy | Stomach (P Malfertheiner, Section Editor)

Autoimmune Gastritis: Update and New Perspectives in Therapeutic Management

Authors: Elisabeth Orgler, Stefanie Dabsch, Peter Malfertheiner, Christian Schulz

Published in: Current Treatment Options in Gastroenterology | Issue 1/2023

Login to get access

Abstract

Purpose of Review

Diagnosis of autoimmune gastritis (AIG) is often delayed because of the absence of typical symptoms. Clinical guidelines are lacking which results in inadequate treatment and poor cancer screening. This review presents an overview of current management options and aims at raising awareness for this often-neglected disease.

Recent Findings

Autoimmune gastritis is mostly thought of as a disease of the elderly with vitamin B12 deficiency and pernicious anemia. Today it is recognized that AIG is found with a similar prevalence among all age-groups, with iron deficiency being a frequent feature. Conventional therapy consists of adequate iron and vitamin B12 supplementation as well as symptomatic approaches. The associated risk for gastric adenocarcinoma and gastric neuroendocrine tumors requires regular endoscopic follow up. Novel therapies aiming to reduce gastric atrophy and cancer risk are currently under development.

Summary

Treatment of autoimmune gastritis should focus on optimizing supplementation of deficiencies and include cancer prevention measures. Clinical research should address the possibility to arrest the inflammatory process and to prevent progression of AIG. International guidelines on management and endoscopic screening intervals should be set up.
Literature
2.
go back to reference Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis—pathogenesis, pathology and Management. Nat Rev Gastroenterol Hepatol. 2013;10:529–41.CrossRefPubMed Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis—pathogenesis, pathology and Management. Nat Rev Gastroenterol Hepatol. 2013;10:529–41.CrossRefPubMed
4.
go back to reference Hershko C, Ronson A, Souroujon M, Maschler I, Heyd J, Patz J. Variable hematologic presentation of autoimmune gastritis: age-related progression from iron deficiency to cobalamin depletion. Blood. 2006;107(4):1673–9.CrossRefPubMed Hershko C, Ronson A, Souroujon M, Maschler I, Heyd J, Patz J. Variable hematologic presentation of autoimmune gastritis: age-related progression from iron deficiency to cobalamin depletion. Blood. 2006;107(4):1673–9.CrossRefPubMed
6.
go back to reference Annibale B, Azzoni C, Corleto VD, Di Giulio E, Caruana P, D’Ambra G, et al. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepatol. 2001;13(12):1449–56.CrossRefPubMed Annibale B, Azzoni C, Corleto VD, Di Giulio E, Caruana P, D’Ambra G, et al. Atrophic body gastritis patients with enterochromaffin-like cell dysplasia are at increased risk for the development of type I gastric carcinoid. Eur J Gastroenterol Hepatol. 2001;13(12):1449–56.CrossRefPubMed
7.
go back to reference Vannella L, Sbrozzi-Vanni A, Lahner E, Bordi C, Pilozzi E, Corleto VD, et al. Development of type i gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther. 2011;33(12):1361–9.CrossRefPubMed Vannella L, Sbrozzi-Vanni A, Lahner E, Bordi C, Pilozzi E, Corleto VD, et al. Development of type i gastric carcinoid in patients with chronic atrophic gastritis. Aliment Pharmacol Ther. 2011;33(12):1361–9.CrossRefPubMed
8.
go back to reference Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988Jul 1;48(13):3554–60.PubMed Correa P. A human model of gastric carcinogenesis. Cancer Res. 1988Jul 1;48(13):3554–60.PubMed
9.
go back to reference Vannella L, Lahner E, Osborn J, Annibale B. Systematic review: gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther. 2013;37(4):375–82.CrossRefPubMed Vannella L, Lahner E, Osborn J, Annibale B. Systematic review: gastric cancer incidence in pernicious anaemia. Aliment Pharmacol Ther. 2013;37(4):375–82.CrossRefPubMed
10.
go back to reference Lahner E, Esposito G, Pilozzi E, Purchiaroni F, Corleto VD, Di Giulio E, et al. Occurrence of gastric cancer and carcinoids in atrophic gastritis during prospective long-term follow up. Scand J Gastroenterol. 2015;50(7):856–65.CrossRefPubMed Lahner E, Esposito G, Pilozzi E, Purchiaroni F, Corleto VD, Di Giulio E, et al. Occurrence of gastric cancer and carcinoids in atrophic gastritis during prospective long-term follow up. Scand J Gastroenterol. 2015;50(7):856–65.CrossRefPubMed
12.
go back to reference Centanni M, Marignani M, Gargano L, Corleto VD, Casini A, Delle Fave G, et al. Atrophic body gastritis in patients with autoimmune thyroid disease: an underdiagnosed association. Arch Intern Med. 1999;159(15):1726–30.CrossRefPubMed Centanni M, Marignani M, Gargano L, Corleto VD, Casini A, Delle Fave G, et al. Atrophic body gastritis in patients with autoimmune thyroid disease: an underdiagnosed association. Arch Intern Med. 1999;159(15):1726–30.CrossRefPubMed
13.
go back to reference Kawanaka M, Tanikawa T, Kamada T, Ishii K, Urata N, Nakamura J, et al. High prevalence of autoimmune gastritis in patients with nonalcoholic steatohepatitis. Intern Med. 2019;58(20):2907–13.CrossRefPubMedPubMedCentral Kawanaka M, Tanikawa T, Kamada T, Ishii K, Urata N, Nakamura J, et al. High prevalence of autoimmune gastritis in patients with nonalcoholic steatohepatitis. Intern Med. 2019;58(20):2907–13.CrossRefPubMedPubMedCentral
14.
go back to reference Zhang Y, Weck MN, Scḧottker B, Rothenbacher D, Brenner H. Gastric parietal cell antibodies, helicobacter pylori infection, and chronic atrophic gastritis: evidence from a large population-based study in germany. Cancer Epidemiol Biomarkers Prev. 2013;22(5):821–6.CrossRefPubMed Zhang Y, Weck MN, Scḧottker B, Rothenbacher D, Brenner H. Gastric parietal cell antibodies, helicobacter pylori infection, and chronic atrophic gastritis: evidence from a large population-based study in germany. Cancer Epidemiol Biomarkers Prev. 2013;22(5):821–6.CrossRefPubMed
15.
go back to reference Wang S-M, Roth MJ, Murphy GA, Dawsey SM, Fan J-H, Taylor PR, Qiao Y-L, Abnet CC. Serologic profile of antiparietal cell antibodies, pepsinogens, and H. pylori and risk of upper gastrointestinal cancer: a nested case–control study in China. Cancer Epidemiol Biomark Prev. 2019;28:2022–9.CrossRef Wang S-M, Roth MJ, Murphy GA, Dawsey SM, Fan J-H, Taylor PR, Qiao Y-L, Abnet CC. Serologic profile of antiparietal cell antibodies, pepsinogens, and H. pylori and risk of upper gastrointestinal cancer: a nested case–control study in China. Cancer Epidemiol Biomark Prev. 2019;28:2022–9.CrossRef
16.
go back to reference • Ko CW, Siddique SM, Patel A, Harris A, Sultan S, Altayar O, et al. AGA clinical practice guidelines on the gastrointestinal evaluation of iron deficiency anemia. Gastroenterology. 2020;159(3):1085–94. https://doi.org/10.1053/j.gastro.2020.06.046. Guideline on anemia and work-up of patients. AIG patients are only imcompletely represented in the guideline recommendations.CrossRefPubMed • Ko CW, Siddique SM, Patel A, Harris A, Sultan S, Altayar O, et al. AGA clinical practice guidelines on the gastrointestinal evaluation of iron deficiency anemia. Gastroenterology. 2020;159(3):1085–94. https://​doi.​org/​10.​1053/​j.​gastro.​2020.​06.​046. Guideline on anemia and work-up of patients. AIG patients are only imcompletely represented in the guideline recommendations.CrossRefPubMed
17.
go back to reference Shayeghi M, Latunde-Dada GO, Oakhill JS, Laftah AH, Takeuchi K, Halliday N, et al. Identification of an intestinal heme transporter. Cell. 2005;122(5):789–801.CrossRefPubMed Shayeghi M, Latunde-Dada GO, Oakhill JS, Laftah AH, Takeuchi K, Halliday N, et al. Identification of an intestinal heme transporter. Cell. 2005;122(5):789–801.CrossRefPubMed
18.
go back to reference Betesh AL, Santa Ana CA, Cole JA, Fordtran JS. Is achlorhydria a cause of iron deficiency anemia?1. Am J Clin Nutr. 2015;102(1):9–19.CrossRefPubMed Betesh AL, Santa Ana CA, Cole JA, Fordtran JS. Is achlorhydria a cause of iron deficiency anemia?1. Am J Clin Nutr. 2015;102(1):9–19.CrossRefPubMed
20.
go back to reference Mohamed M, Thio J, Thomas RS, Phillips J. Pernicious anaemia. BMJ; 2020. p. m1319. Mohamed M, Thio J, Thomas RS, Phillips J. Pernicious anaemia. BMJ; 2020. p. m1319.
22.
go back to reference Lahner E, Norman GL, Severi C, Encabo S, Shums Z, Vannella L, et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol. 2009;104(8):2071–9.CrossRefPubMed Lahner E, Norman GL, Severi C, Encabo S, Shums Z, Vannella L, et al. Reassessment of intrinsic factor and parietal cell autoantibodies in atrophic gastritis with respect to cobalamin deficiency. Am J Gastroenterol. 2009;104(8):2071–9.CrossRefPubMed
24.
go back to reference Koivurova OP, Koskela R, Blomster T, et al. Serological biomarker panel in diagnosis of atrophic gastritis and Helicobacter pylori infection in gastroscopy referral patients: clinical validation of the new-generation gastropanel®test. Anticancer Res. 2021;41:5527–37.CrossRefPubMed Koivurova OP, Koskela R, Blomster T, et al. Serological biomarker panel in diagnosis of atrophic gastritis and Helicobacter pylori infection in gastroscopy referral patients: clinical validation of the new-generation gastropanel®test. Anticancer Res. 2021;41:5527–37.CrossRefPubMed
25.
go back to reference Yang YX, Brill J, Krishnan P, Leontiadis G. American Gastroenterological Association Institute Guideline on the role of upper gastrointestinal biopsy to evaluate dyspepsia in the adult patient in the absence of visible mucosal lesions. Gastroenterology. 2015;149(4):1082–7.CrossRefPubMed Yang YX, Brill J, Krishnan P, Leontiadis G. American Gastroenterological Association Institute Guideline on the role of upper gastrointestinal biopsy to evaluate dyspepsia in the adult patient in the absence of visible mucosal lesions. Gastroenterology. 2015;149(4):1082–7.CrossRefPubMed
26.
27.
go back to reference •• Pimentel-Nunes P, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Port. Endoscopy. 2019;51(4):365–88. The only guideline on screening managment of AIG patients currently available.CrossRefPubMed •• Pimentel-Nunes P, Libânio D, Marcos-Pinto R, Areia M, Leja M, Esposito G, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Port. Endoscopy. 2019;51(4):365–88. The only guideline on screening managment of AIG patients currently available.CrossRefPubMed
28.
go back to reference Ghosh T, Lewis DI, Axon ATR, Everett SM. Review article: methods of measuring gastric acid secretion. Aliment Pharmacol Ther. 2011;33(7):768–81.CrossRefPubMed Ghosh T, Lewis DI, Axon ATR, Everett SM. Review article: methods of measuring gastric acid secretion. Aliment Pharmacol Ther. 2011;33(7):768–81.CrossRefPubMed
29.
go back to reference Zullo A, Germanà B, Galliani E, Khalaf K, Hassan C, Monica F. Real-time determination of gastric juice pH with EndoFaster® for atrophic gastritis assessment. Dig Liver Dis. 2022;54(12):1646–8.CrossRefPubMed Zullo A, Germanà B, Galliani E, Khalaf K, Hassan C, Monica F. Real-time determination of gastric juice pH with EndoFaster® for atrophic gastritis assessment. Dig Liver Dis. 2022;54(12):1646–8.CrossRefPubMed
30.
go back to reference Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut. 2007;56(5):631–6.CrossRefPubMed Rugge M, Meggio A, Pennelli G, Piscioli F, Giacomelli L, De Pretis G, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut. 2007;56(5):631–6.CrossRefPubMed
31.
go back to reference Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008;40(8):650–8.CrossRefPubMed Rugge M, Correa P, Di Mario F, El-Omar E, Fiocca R, Geboes K, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008;40(8):650–8.CrossRefPubMed
32.
go back to reference •• Weise F, Vieth M, Reinhold D, Haybaeck J, Goni E, Lippert H, et al. Gastric cancer in autoimmune gastritis: a case-control study from the German centers of the staR project on gastric cancer research. United Eur Gastroenterol J. 2020;8(2):175–84. A current study on the risk of gastric neopalsia in AIG.CrossRef •• Weise F, Vieth M, Reinhold D, Haybaeck J, Goni E, Lippert H, et al. Gastric cancer in autoimmune gastritis: a case-control study from the German centers of the staR project on gastric cancer research. United Eur Gastroenterol J. 2020;8(2):175–84. A current study on the risk of gastric neopalsia in AIG.CrossRef
33.
go back to reference •• Gomez-Cifuentes JD, Jordan-Sparkman DYG. Management of upper gastrointestinal symptoms in patients with autoimmune gastritis. Curr Opin Gastroenterol. 2022;38(6):600–6. Often management of GI symptoms in AIG is neglected, here advice on this matter is provided.CrossRef •• Gomez-Cifuentes JD, Jordan-Sparkman DYG. Management of upper gastrointestinal symptoms in patients with autoimmune gastritis. Curr Opin Gastroenterol. 2022;38(6):600–6. Often management of GI symptoms in AIG is neglected, here advice on this matter is provided.CrossRef
34.
go back to reference Pilotto V, Maddalo G, Orlando C, Fassan M, Rugge M, Farinati F, et al. Objective evidence of gastro-esophageal reflux disease is rare in patients with autoimmune gastritis. J Gastrointest Liver Dis. 2021;30(1):30–6.CrossRef Pilotto V, Maddalo G, Orlando C, Fassan M, Rugge M, Farinati F, et al. Objective evidence of gastro-esophageal reflux disease is rare in patients with autoimmune gastritis. J Gastrointest Liver Dis. 2021;30(1):30–6.CrossRef
35.
go back to reference Miceli E, Lenti MV, Padula D, Luinetti O, Vattiato C, Monti CM, et al. Common features of patients with autoimmune atrophic gastritis. Clin Gastroenterol Hepatol. 2012;10(7):812–4.CrossRefPubMed Miceli E, Lenti MV, Padula D, Luinetti O, Vattiato C, Monti CM, et al. Common features of patients with autoimmune atrophic gastritis. Clin Gastroenterol Hepatol. 2012;10(7):812–4.CrossRefPubMed
36.
go back to reference Carabotti M, Esposito G, Lahner E, Pilozzi E, Conti L, Ranazzi G, Severi C, Bellini M, Annibale B. Gastroesophageal reflux symptoms and microscopic esophagitis in a cohort of consecutive patients affected by atrophic body gastritis: a pilot study. Scand J Gastroenterol. 2019;54:35–40.CrossRefPubMed Carabotti M, Esposito G, Lahner E, Pilozzi E, Conti L, Ranazzi G, Severi C, Bellini M, Annibale B. Gastroesophageal reflux symptoms and microscopic esophagitis in a cohort of consecutive patients affected by atrophic body gastritis: a pilot study. Scand J Gastroenterol. 2019;54:35–40.CrossRefPubMed
37.
go back to reference Tenca A, Massironi S, Pugliese D, Consonni D, Mauro A, Cavalcoli F, et al. Gastro-esophageal reflux and antisecretory drugs use among patients with chronic autoimmune atrophic gastritis: a study with pH-impedance monitoring. Neurogastroenterol Motil. 2016;28(2):274–80.CrossRefPubMed Tenca A, Massironi S, Pugliese D, Consonni D, Mauro A, Cavalcoli F, et al. Gastro-esophageal reflux and antisecretory drugs use among patients with chronic autoimmune atrophic gastritis: a study with pH-impedance monitoring. Neurogastroenterol Motil. 2016;28(2):274–80.CrossRefPubMed
38.
go back to reference Kužela L. Small intestinal bacterial overgrowth syndrome. Gastroenterol a Hepatol. 2015;69(1):70–2.CrossRef Kužela L. Small intestinal bacterial overgrowth syndrome. Gastroenterol a Hepatol. 2015;69(1):70–2.CrossRef
39.
go back to reference Gatta L, Scarpignato C, McCallum RW, Lombardo L, Pimentel M, D’Incà R, et al. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45(5):604–16.CrossRefPubMedPubMedCentral Gatta L, Scarpignato C, McCallum RW, Lombardo L, Pimentel M, D’Incà R, et al. Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth. Aliment Pharmacol Ther. 2017;45(5):604–16.CrossRefPubMedPubMedCentral
40.
go back to reference Zhong C, Qu C, Wang B, Liang S, Zeng B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth. J Clin Gastroenterol. 2017;51(4):300–11.CrossRefPubMed Zhong C, Qu C, Wang B, Liang S, Zeng B. Probiotics for Preventing and Treating Small Intestinal Bacterial Overgrowth. J Clin Gastroenterol. 2017;51(4):300–11.CrossRefPubMed
42.
go back to reference Cavalcoli F, Zilli A, Conte D, Massironi S. Micronutrient deficiencies in patients with chronic atrophic autoimmune gastritis: a review. World J Gastroenterol. 2017;23(4):563–72.CrossRefPubMedPubMedCentral Cavalcoli F, Zilli A, Conte D, Massironi S. Micronutrient deficiencies in patients with chronic atrophic autoimmune gastritis: a review. World J Gastroenterol. 2017;23(4):563–72.CrossRefPubMedPubMedCentral
43.
go back to reference Kim HW, Kim YH, Han K, Nam GE, Kim GS, Han BD, et al. Atrophic gastritis: a related factor for osteoporosis in elderly women. PLoS ONE. 2014;9(7):5–9.CrossRef Kim HW, Kim YH, Han K, Nam GE, Kim GS, Han BD, et al. Atrophic gastritis: a related factor for osteoporosis in elderly women. PLoS ONE. 2014;9(7):5–9.CrossRef
45.
go back to reference Rugge M, Fassan M, Pizzi M, Zorzetto V, Maddalo G, Realdon S, et al. Autoimmune gastritis: histology phenotype and OLGA staging. Aliment Pharmacol Ther. 2012;35(12):1460–6.CrossRefPubMed Rugge M, Fassan M, Pizzi M, Zorzetto V, Maddalo G, Realdon S, et al. Autoimmune gastritis: histology phenotype and OLGA staging. Aliment Pharmacol Ther. 2012;35(12):1460–6.CrossRefPubMed
47.
go back to reference Di Mario F, Rodriguez-Castro KI, Franceschi M, Landi S, Grillo S, Franzoni L, Russo M, Brandimarte G, Tursi A, Crafa P. Improvement of symptoms in patients affected by chronic atrophic gastritis using L-cysteine [acetium®]. Digestive Diseases. (2022) https://doi.org/10.1159/000528168 Di Mario F, Rodriguez-Castro KI, Franceschi M, Landi S, Grillo S, Franzoni L, Russo M, Brandimarte G, Tursi A, Crafa P. Improvement of symptoms in patients affected by chronic atrophic gastritis using L-cysteine [acetium®]. Digestive Diseases. (2022) https://​doi.​org/​10.​1159/​000528168
48.
go back to reference Jeffries GH, Todd JE, Sleisenger MH. The effect of prednisolone on gastric mucosal histology, gastric secretion, and vitamin B 12 absorption in patients with pernicious anemia. J Clin Invest. 1966;45(5):803–12.CrossRefPubMedPubMedCentral Jeffries GH, Todd JE, Sleisenger MH. The effect of prednisolone on gastric mucosal histology, gastric secretion, and vitamin B 12 absorption in patients with pernicious anemia. J Clin Invest. 1966;45(5):803–12.CrossRefPubMedPubMedCentral
50.
go back to reference Moore AR, Boyce M, Steele IA, Campbell F, Varro A, Pritchard DM. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS ONE. 2013;8(10):1–12.CrossRef Moore AR, Boyce M, Steele IA, Campbell F, Varro A, Pritchard DM. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS ONE. 2013;8(10):1–12.CrossRef
51.
go back to reference Boyce M, Moore AR, Sagatun L, Parsons BN, Varro A, Campbell F, Fossmark R, Waldum HL, Pritchard DM. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. Br J Clin Pharmacol. 2016;83:466–75. Boyce M, Moore AR, Sagatun L, Parsons BN, Varro A, Campbell F, Fossmark R, Waldum HL, Pritchard DM. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis. Br J Clin Pharmacol. 2016;83:466–75.
Metadata
Title
Autoimmune Gastritis: Update and New Perspectives in Therapeutic Management
Authors
Elisabeth Orgler
Stefanie Dabsch
Peter Malfertheiner
Christian Schulz
Publication date
02-03-2023
Publisher
Springer US
Published in
Current Treatment Options in Gastroenterology / Issue 1/2023
Print ISSN: 1092-8472
Electronic ISSN: 1534-309X
DOI
https://doi.org/10.1007/s11938-023-00406-4

Other articles of this Issue 1/2023

Current Treatment Options in Gastroenterology 1/2023 Go to the issue

Esophagus (K Ravi, Section Editor)

Management of Esophageal Diverticula

Nutrition and Obesity (C Newberry, Section Editor)

The Role of the Gastroenterologist in Modern Nutrition Support Services

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.